From: Delivery of stromal cell-derived factor 1α for in situ tissue regeneration
Bonding strategy | Features | Applications (SM; LC; LE) | References | |
---|---|---|---|---|
| Direct loading or adsorption | Ease of operation; burst release; short release duration; poor loading efficiency | hydroxyethyl methacrylate (HEMA) /hyaluronic acid (HA) hydrogels; SDF-1α: 4 μg/ml | [31] |
PCL and type B-gelatin; SDF-1α:2.5 ~ 10 μg/ml | [19] | |||
| Immobilization through the formation of ionic complexes | Extensive applicability; efficient dsorption; free of linker molecules; less dependent on surface properties; adjustable release rate; requires cytotoxic surfactants | PGS (PEDA/heparin coacervate); SDF-1α:8 μg/ml Efficiency:94.3% | [51] |
PPCN; SDF-1α:0.5 μg /ml Efficiency:102.8% | [49] | |||
| Immobilization through specific heparin-mediated interaction | Anti-thrombogenicity; efficient adsorption; prevent enzymolysis; sustained release; complex operation | 19%PLLA 5%PCL (w/v); SDF-1α:0.5 μg /ml | [47] |
StarPEG-heparin hydrogel; SDF-1α:2.5 ~ 15 μg/ml; Efficiency:99.6% | [57] | |||
Co-Cr plates; SDF-1α:0.25 ~ 2 μg/ml | [61] | |||
| Particulate systems | Sustained release; long release duration; multiple proteins load; complex operation | Dex-GMA/gelatin microcapsules (PNIPAAm thermo gates); SDF-1α:0.1 μg /ml Efficiency:97.5% | [20] |
PLGA nanoparticles | [27] |